MedTrace Logo

Clinical Study of DC-CIK Cells as a Post-remission Treatment for Malignant Tumors

NCT04292769 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2020-03-03

No results posted yet for this study

Summary

1. Screening stage
2. Evaluation of disease
3. Grouping of patients
4. Infusion of cells
5. Surveillance of adverse effect

Conditions

  • Malignant Neoplasm

Interventions

DRUG

Decitabine

Decitabine 10mg / d, intravenous administration d-5 ～ d-1

BIOLOGICAL

DC-CIK

Autologous DC-CIK cell infusion: the first course: d1-d3, the second course: d14-d16; the total number of cells is about 5-10 × 109;

Sponsors & Collaborators

  • Li Yu

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-21
Primary Completion
2023-01-20
Completion
2023-01-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04292769 on ClinicalTrials.gov